Sarah Diggelmann
Overview
Explore the profile of Sarah Diggelmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
268
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eckmann J, Fauti T, Biehl M, Zabaleta A, Blanco L, Lelios I, et al.
Blood
. 2024 Oct;
145(2):202-219.
PMID: 39476124
Despite several approved therapies, multiple myeloma (MM) remains an incurable disease with high unmet medical need. "Off-the-shelf" T-cell bispecific antibodies (TCBs) targeting B-cell maturation antigen (BCMA) and G protein-coupled receptor...
2.
Van De Vyver A, Weinzierl T, Eigenmann M, Frances N, Herter S, Buser R, et al.
Mol Cancer Ther
. 2020 Dec;
20(2):357-366.
PMID: 33298591
Targeted T-cell redirection is a promising field in cancer immunotherapy. T-cell bispecific antibodies (TCB) are novel antibody constructs capable of binding simultaneously to T cells and tumor cells, allowing cross-linking...
3.
Claus C, Ferrara C, Xu W, Sam J, Lang S, Uhlenbrock F, et al.
Sci Transl Med
. 2019 Jun;
11(496).
PMID: 31189721
Endogenous costimulatory molecules on T cells such as 4-1BB (CD137) can be leveraged for cancer immunotherapy. Systemic administration of agonistic anti-4-1BB antibodies, although effective preclinically, has not advanced to phase...
4.
Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, et al.
Clin Cancer Res
. 2018 May;
24(19):4785-4797.
PMID: 29716920
Despite promising clinical activity, T-cell-engaging therapies including T-cell bispecific antibodies (TCB) are associated with severe side effects requiring the use of step-up-dosing (SUD) regimens to mitigate safety. Here, we present...
5.
Caspers P, Locher H, Pfaff P, Diggelmann S, Rueedi G, Bur D, et al.
Antimicrob Agents Chemother
. 2017 Jun;
61(8).
PMID: 28584149
Cadazolid (CDZ) is a new antibiotic currently in clinical development for the treatment of infections. CDZ interferes with the bacterial protein synthesis machinery. The aim of the present study was...